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INTRODUCTION
A transformation of regulatory toxicology is underway to meet the demands of testing increasing
numbers of chemicals whilst reducing reliance on in vivomodels. This transformation requires a shift
from chemical safety assessment largely based on direct empirical observation of apical toxicity
outcomes in whole organisms to predictive approaches in which outcomes and risks are inferred
from accumulated mechanistic understanding. In the last decade, Adverse Outcome Pathways
(AOPs) (Ankley et al., 2010; Ankley and Edwards, 2018) have captured the attention of regulators
and researchers alike as a systematic approach for organizing knowledge that may support such
inferences (Wittwehr et al., 2017).
An AOP is a conceptual structured representation of existing toxicological knowledge describing
the causally connected sequence of events, across different levels of biological organization, required
to produce an adverse effect when an organism is exposed to a stressor. Specifically, AOPs depict a
series of key events (KEs) linking a molecular initiating event (MIE, an interaction between a stressor
(e.g., endogenous ligand, xenobiotic) and a biomolecule) to an adverse outcome (AO, at organism or
population levels). The causal links between 2 KEs are referred to as key event relationships (KERs).
AOPs provide a useful framework to connect mechanistic data to adverse effects on human health or
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TABLE 1 | EM AOPs in AOP-wiki.
















52 18 8 24 35 (Dev: 14,
Rev: 13, Apr: 1,
End: 7)
Related to androgen axis (15 AOPs)
PPARα activation in utero leading to impaired fertility in
males
18 x EAGMST Under
review (Rev.)
Androgen receptor antagonism leading to adverse
effects in the male foetus (mammals)
19 x x
Androgen receptor agonism leading to reproductive
dysfunction (in repeat-spawning fish)
23 x WPHA/WNT
Endorsed (End.)
Decrease in androgen receptor activity leading to
Leydig cell tumors (in rat)
111 x x
Androgen receptor activation leading to hepatocellular
adenomas and carcinomas (in mouse and rat)
117 x Under
development (Dev.)
HMG-CoA reductase inhibition leading to decreased
fertility
124 x x
Inhibition of 17α-hydrolase/C 10,20-lyase (Cyp17A1)
activity leads to birth reproductive defects
(cryptorchidism) in male (mammals)
288 x
5α-reductase inhibition leading to short anogenital
distance (AGD) in male (mammalian) offspring
305 x Dev
Androgen receptor (AR) antagonism leading to short
anogenital distance (AGD) in male (mammalian) offspring
306 Dev
Decreased testosterone synthesis leading to short
anogenital distance (AGD) in male (mammalian) offspring
307 x Dev
Androgen receptor (AR) antagonism leading to nipple
retention (NR) in male (mammalian) offspring
344 x
Androgen receptor (AR) antagonism leading to
decreased fertility in females
345 x
Inhibition of 11β-Hydroxysteroid Dehydrogenase
leading to decreased population trajectory
348 x
Androgen receptor antagonism leading to testicular
cancer
372 x
Androgen receptor agonism leading to male-biased
sex ratio
376 x
Related to estrogen axis (24 AOPs)
Aromatase inhibition leading to reproductive
dysfunction
25 x End
Estrogen receptor agonism leading to reproductive
dysfunction
29 x x
Estrogen receptor antagonism leading to reproductive
dysfunction
30 x Rev
Sustained AhR Activation leading to Rodent Liver
Tumours
41 x Rev
Constitutive androstane receptor activation leading to
hepatocellular adenomas and carcinomas in the mouse
and the rat
107 x Rev
Increased dopaminergic activity leading to endometrial
adenocarcinomas (in Wistar rat)
112 x x
Aryl hydrocarbon receptor activation leading to
uroporphyria
131 x End
Endocytic lysosomal uptake leading to liver fibrosis 144 x Rev
Estrogen Receptor Activation and Female Precocious
Puberty
146 x x
Aryl hydrocarbon receptor activation leading to early life
stage mortality, via reduced VEGF
150 x End
165 x x
(Continued on following page)
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TABLE 1 | (Continued) EM AOPs in AOP-wiki.
















52 18 8 24 35 (Dev: 14,
Rev: 13, Apr: 1,
End: 7)
Antiestrogen activity leading to ovarian adenomas and
granular cell tumors in the mouse
Early-life estrogen receptor activity leading to
endometrial carcinoma in the mouse.
167 x x
Estrogen receptor activation leading to breast cancer 200 x x
Cyp2E1 Activation Leading to Liver Cancer 220 x End
Deposition of energy leading to lung cancer 272 x Rev
Inhibition of 5α-reductase leading to impaired fecundity
in female fish
289 x Dev
Increased DNA damage leading to increased risk of
breast cancer
293 x Dev
Increased reactive oxygen and nitrogen species
(RONS) leading to increased risk of breast cancer
294 x Dev
Early-life stromal estrogen receptor activation by
endocrine disrupting chemicals in the mammary gland
leading to enhanced cancer risk
295 x Dev
Binding to estrogen receptor (ER)-α in immune cells
leading to exacerbation of systemic lupus
erythematosus (SLE)
314 x Dev
Glucocorticoid Receptor Agonism Leading to Impaired
Fin Regeneration
334 x
Aromatase inhibition leads to male-biased sex ratio via
impacts on gonad differentiation
346 x
Decreased fibrinolysis and activated bradykinin system
leading to hyperinflammation
392 x
G protein-coupled estrogen receptor 1 (GPER) signal
pathway in the endocrine disrupting effect
401 x
Related to thyroid axis (31 AOPs)
Aromatase (Cyp19a1) reduction leading to impaired
fertility in adult female
7 x Rev
Upregulation of Thyroid Hormone catabolism via
Activation of Hepatic Nuclear Receptors, and
Subsequent Adverse Neurodevelopmental Outcomes in
Mammals
8 Not under active
development
Dev
Protein Alkylation leading to Liver Fibrosis 38 x x
Inhibition of Thyroperoxidase and Subsequent Adverse
Neurodevelopmental Outcomes in Mammals
42 x End
Inhibition of Na+/I- symporter (NIS) leads to learning
and memory impairment
54 x End
Inhibition of iodide pump activity leading to follicular cell
adenomas and carcinomas (in rat and mouse)
110 x x
Inhibition of thyroid peroxidase leading to follicular cell
adenomas and carcinomas (in rat and mouse)
119 x x
Kidney dysfunction by decreased thyroid hormone 128 x Dev
Sodium Iodide Symporter (NIS) Inhibition and
Subsequent Adverse Neurodevelopmental Outcomes in
Mammals
134 x x
Interference with thyroid serum binding protein
transthyretin and subsequent adverse human
neurodevelopmental toxicity
152 x Dev
Deiodinase 2 inhibition leading to increased mortality
via reduced posterior swim bladder inflation
155 x Rev
Deiodinase 2 inhibition leading to increased mortality
via reduced anterior swim bladder inflation
156 x Rev
(Continued on following page)
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TABLE 1 | (Continued) EM AOPs in AOP-wiki.
















52 18 8 24 35 (Dev: 14,
Rev: 13, Apr: 1,
End: 7)
Deiodinase 1 inhibition leading to increased mortality
via reduced posterior swim bladder inflation
157 x Rev
Deiodinase 1 inhibition leading to increased mortality
via reduced anterior swim bladder inflation
158 x Rev
Thyroperoxidase inhibition leading to increased
mortality via reduced anterior swim bladder inflation
159 x Rev
Enhanced hepatic clearance of thyroid hormones
leading to thyroid follicular cell adenomas and
carcinomas in the rat and mouse
162 x x
Thyroperoxidase inhibition leading to altered
amphibian metamorphosis
175 x x
Sodium Iodide Symporter (NIS) Inhibition leading to
altered amphibian metamorphosis
176 x x
Iodotyrosine deiodinase (IYD) inhibition leading to
altered amphibian metamorphosis
188 x x
Type I iodothyronine deiodinase (DIO1) inhibition
leading to altered amphibian metamorphosis
189 x x
Type II iodothyronine deiodinase (DIO2) inhibition
leading to altered amphibian metamorphosis
190 x x
Type III iodotyrosine deiodinase (DIO3) inhibition
leading to altered amphibian metamorphosis
191 x x
Inhibition of thyroid peroxidase leading to impaired
fertility in fish
271 x Dev






Thyroid Receptor Antagonism and Subsequent
Adverse Neurodevelopmental Outcomes in Mammals
300 x Dev
Thyroperoxidase inhibition leading to increased
mortality via altered retinal layer structure
363 x
Competitive binding to thyroid hormone carrier protein
transthyretin (TTR) leading to altered amphibian
metamorphosis
366 x
Competitive binding to thyroid hormone carrier protein
thyroid binding globulin (TBG) leading to altered
amphibian metamorphosis
367 x
AOP for thyroid disorder caused by triphenyl
phosphate
393 x
Inhibition of Fyna leading to increased mortality via
decreased eye size (Microphthalmos)
399 x
Thyroid peroxidase (TPO) inhibition leads to




Ecdysone receptor agonism leading to incomplete
ecdysis associated mortality
4 x x
GnRH pulse disruption leading to pituitary adenomas
and carcinomas in the SD rat
169 x x
Anti-dopaminergic activity leading to mammary
adenomas and carcinomas in the SD rat
170 x x
Type I iodothyronine deiodinase (DIO1) inhibition
leading to altered amphibian metamorphosis
189 x x
Juvenile hormone receptor agonism leading to male
offspring induction associated population decline
201 x x
309 x
(Continued on following page)
Frontiers in Toxicology | www.frontiersin.org December 2021 | Volume 3 | Article 7870174
Audouze et al. Evidence-Based Approaches for Endocrine-Mediated AOPs
wildlife populations as a basis for the identification of cell- or
biochemical-based tests that could fit in Integrated Approaches to
Testing and Assessment (IATAs), identifying KEs that could be
targeted for the development of New Approach Methods
(NAMs), as well as investigating similarities in mechanistic
pathways between species.
AOPs are also particularly salient for identifying potential
Endocrine Disruptors (EDs). Indeed, both the World Health
Organization (WHO) and the International Programme on
Chemical Safety (IPCS) definition and the scientific criteria
adopted by the European Union in 2017 are articulated around
three key requirements, namely; evidence of an adverse effect,
evidence of an endocrine-mediated (EM) mode-of-action, and the
plausibility of the causal relationship between the mode-of-action
and adverse effect. Both the European Chemical Agency (ECHA)
and European Food Safety Authority (EFSA) recommend that
more EM AOPs be developed for substantiation of chemicals’ ED
properties [European Chemical Agency (ECHA) et al., 2018]. Of
the 370 AOPs currently included in the AOP-wiki (aopwiki.org),
there are 80 EM AOPs (Table 1).
Evidence-Based Methodologies (EBMs), including
systematic maps and systematic reviews (SRs), aim to help
assemble and assess the current knowledge on a topic in an
objective, comprehensive and transparent manner. Although
the AOP development process does not currently explicitly
require use of EBMs (De Vries et al., 2021), efforts are ongoing
to recommend AOP developers to document the most
important aspects of their work, including the overall data
identification, screening and evaluation strategy. EBMs
adapted to AOP development, are desirable to increase
transparency and promote the re-use of AOP components
and their underlying data, and to inform the use for specific
applications by the regulators. Nevertheless, these advantages
need to be balanced with time and effort involved in their
implementation. There is therefore an urgent need to further
develop automated or semi-automated Machine Learning
Tools (MLT) that can assist with specific steps of systematic
evidence retrieval and assessment.
This perspective article draws on lessons learnt from the
EURION cluster activities to review the circumstances in
which EBMs approaches may be most usefully applied to EM
AOP development and opportunities for further research and
development of tools tailored to mechanistic evidence gathering
and evaluation.
EURION ACTIVITIES RELEVANT TO AOP
DEVELOPMENT
EURION is a cluster of eight research projects, funded under the
European Commission’s Horizon 2020 Research and Innovation
Programme, focusing on developing new testing and screening
methods identifying EDs and studying their effects on
metabolism (Audouze et al., 2020; Küblbeck et al., 2020; Legler
et al., 2020), female reproductive toxicity (van Duursen et al.,
2020), developmental neurotoxicity (Lupu et al., 2020) and
thyroid-mediated toxicity (Holbech et al., 2020; Kortenkamp
et al., 2020; Moroni et al., 2020). AOP development is an
integral part of each of these projects (Street et al., 2021).
However, limited availability of test methods assessing EDs
leave significant knowledge gaps in identification of EDs
properties (European Commission. Joint Research Centre,
2017), that can be highlighted through modelling of
underlying mechanisms of action and delineation of AOPs. In
some cases, the MIE is known and endpoints can be
experimentally observed. For example, in the thyroid hormone
system, inhibition of thyroid peroxidase (involved in thyroid
hormones (TH) production) has been associated with the
formation of periventricular heterotopia, symptomatic
disruption of thyroid-dependent neuronal migration (Ramhøj
et al., 2021), yet not currently adequately investigated by available
test guidelines (Kortenkamp et al., 2020).
TABLE 1 | (Continued) EM AOPs in AOP-wiki.
















52 18 8 24 35 (Dev: 14,
Rev: 13, Apr: 1,
End: 7)
Luteinizing hormone receptor antagonism leading to
reproductive dysfunction
PPARalpha Agonism Impairs Fish Reproduction 323 x
Inhibition of 11β-hydroxylase leading to decreased
population trajectory
349 x
Chitin synthase 1 inhibition leading to mortality 360 x EAGMST
approved (Apr.)
Photosystem II antagonism leading to growth inhibition
via dysregulation of growth hormone
371 x
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AOP development within the EURION cluster is ongoing for
different modalities, particularly, those related to androgen,
thyroid hormone, and retinoid signalling. An AOP working
group (WG) has been set up to support and facilitate AOP-
related activities within the EURION projects and to bring
together AOP-structured information and data across projects.
This WG has identified potential synergies and areas for
collaboration among projects for which EBMs may be relevant.
Collaborative AOP development could be supported by
mapping the underlying canonical knowledge on the general
biology of the endocrine system as well as relevant well-
established pathologies. In particular, it may be helpful to
uncouple the development of downstream KER descriptions,
which are related to general/apical organismal effects or
processes that can be described based on canonical knowledge
and are relevant to many different AOPs, from the description of
upstream mechanistic KERs that are often highly specific to a
particular toxicological context. Further, KEs and KERs may be
shared by several AOPs, forming AOP networks. Linear pathways
can converge and diverge several times (Knapen et al., 2018)
producing crossover nodal points in the network. An example is
decreased TH, which is involved in AOs in foetal
neurodevelopment irrespective of the MIE. KE or KER
descriptions therefore emerge as promising units of
collaborative AOP development uncoupled from the MIE
(Svingen et al., 2021). Since KERs are putatively causally-
related pairs of events, they are amenable to evaluation in a
similar way to an exposure-outcome pair conventionally
investigated in an EBM approach (i.e., SRs). A potential
application of EBM in AOP development may therefore be as
a series of KERs’ SRs (De Vries et al., 2021).
EVIDENCE-BASED PROTOCOL
A central premise of EBMs is that protocols be developed and
published or registered a priori to avoid introducing bias.
Applying a similar requirement to the development of AOPs
ought to consider the iterative nature of AOP development and
focus on identifying KERs most amenable to systematically
gathering and assessing existing literature.
Establishing a Priori Biological Plausibility
Whilst the nature of KERs allows them to be “good” EBMs
products, some good practices in their conception would make
them even more SR-compatible. Whether for the construction of
an AOP de novo, or for the addition of KEs to an existing AOP,
KERs should be defined with enough specificity to give AOP users
a clear idea of measurable objects at each step of the AOP state.
Ideally, a clear and transparent rationale for the consideration of a
specific KER ought to be established a priori. This requires
integrating knowledge beyond the realm of regulatory
toxicology, and this point is particularly relevant for EM
pathways. Not only is a grasp of canonical knowledge a
prerequisite but it should also be completed by evidence of
medical conditions such as known hormonal imbalances or
genetic defects in proteins (e.g., receptors, enzymes), as well as
the physiology and signalling pathways of endogenous ligands or
well-characterised (pharmacological) agonists or antagonists
especially relevant to the KE of interest. For instance, the
Allan-Herndon-Dudley syndrome is caused by a rare defect in
the gene encoding for monocarboxylate transporter 8 (MCT8)
that leads to severe brain development deficits (impaired TH
transport across brain cell membranes). Literature related to
clinical presentation and putative pharmacological
interventions (Grijota-Martínez et al., 2020), as well as
evidence of the existence of xenobiotics capable of inhibiting
MCT8 (Johannes et al., 2016), represent important contextual
information when considering the biological plausibility of
inhibition of triiodothyronine (T3) uptake by MCT8 as a
potential MIE. It is therefore clear that a substantial review
effort has to take place during problem formulation (PF) prior
to the formulation of objectives. This may take the form of a
systematic evidence map, wider in scope than a SR, the results of
which could then form the basis of more targeted SRs of the
evidence in relation to knowledge gaps identified.
Problem Formulation and Applicability
Domain
PF is a crucial first step for the development of both a proposed
AOP and protocol for EBMs. The issue presented here concerns
the structured terms used to define a specific context that narrows
the applicability of the KER, and the universality of the AOP. This
process mirrors that of developing PECO (Population, Exposure,
Comparator, Outcome) or similar statements used in EBMs. One
single KER should avoid compounding events together and rather
refer to one single measurable event (OECD, 2018). For instance,
using the expression “fatty acid beta oxidation” is more precise
and useful for EBMs, especially SRs, than the broad statement
“lipid metabolism”. It is easier to retrieve evidence concerning
specific KEs measured with reliable and relevant methods, than to
investigate broad and general phenomena. Specificity and
precision have the advantage of making a KER more
searchable. Notably, an artificial intelligence based approach
using text mining and graph theory, named AOP-helpFinder,
allows to automatically identify and extract specific AOP-related
terms and evidence (aop-helpfinder.u-paris-sciences.fr) (Jornod
et al., 2020; Jornod et al., 2021; Zgheib et al., 2021). In “Rugard
et al., 2020”, AOP-helpFinder results pointed out linkages
between Bisphenol-F and relevant MIEs [i.e., “PPARc
inhibition” (Peroxisome proliferator-activated receptor γ)]
often associated with liver steatosis and lipid accumulation
(Yang et al., 2010).
Another key parameter is the biological domain of
applicability (e.g., taxonomy, sex, species, life stage). In theory,
an AOP’s relevant biological domain of applicability is restricted
to the narrowest domain of its components. For a specific KER,
query terms should remain inclusive as long as the observed
biological object (e.g., protein, organ) and its function are
conserved across the domain category. However, restriction of
the biological context becomes a must when equivalency of the
structure or the function are not preserved. Typically,
translational considerations should take into account the
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relevance of predicting AOs in humans from experimental animal
models. For instance, certain female reproductive endpoints (e.g.,
menstruation, endometriosis, placentation) in humans are absent
or different in rodents, and vice versa (e.g., aromatase inhibition
caused dystocia) (Bruner-Tran et al., 2018). This emphasises the
importance of evolutionary biology and comparative
endocrinology. Concretely, if a KER involves binding to a
specific nuclear receptor, but a certain species lacks a
functional homolog of that receptor, the AOP would not be
relevant to that species on the basis of a lack of conserved
structure. Likewise, KERs involving measurements in ovary
tissue would be restricted to females, and those concerning
hepatic enzymes would be reserved to liver-inclusive AOPs
(OECD, 2018). For example, in their study of 2016, “Schulz
and Sisk, 2016” displayed an interesting example of sex- and life-
specific organizational effects of sex steroids on reproductive
behaviour during brain development. Bioinformatics and
sequence similarity approaches have been adapted and
employed for AOPs of human health and environment
(LaLone et al., 2016, 2013). LaLone et al. (2018) showcased the
use of sequence alignment to predict across species susceptibility
(SeqAPASS) for species extrapolation from high-throughput
screening results including case studies on evidence for
conservation of certain endocrine targets across vertebrate
species.
Search Strategies
The design of adequately sensitive and sufficiently specific
systematic literature search strategies for AOP development,
particularly when a KE is used as a starting point, is
challenging. AOPs are assumed to be chemical agnostic, i.e.,
their applicability should not be limited to a specific
substance. However, search strategies employed in EBMs are
typically articulated around search terms related to both the
stressor (exposure) and the outcome (endpoint). The chemical
agnosticism of AOPs raises questions over the validity of
literature search strategies referring to specific substances.
Nevertheless, the evidence used to support each KER is based
on chemical-specific exposure data (Leist et al., 2017). However,
since in reality we are usually simultaneously exposed to mixtures
of exposures and rarely to single chemicals, carrying on multiple
chemical-specific search analyses, concerning different stressors,
and combining their results, might pull out, at least partially, the
approach from chemical-specificity towards chemical-
agnosticism again. Conversely, many chemical stressors can
putatively interfere with one or several AOPs and this is
another case where combination of search strategies would be
relevant for regulatory decision-making (Aguayo-Orozco et al.,
2019).
These facts unveil the complexity of interactions in biology
and allow to detect a balance point for the adequate approach
between chemical-independency and chemical-specificity.
Therefore, search strategies using generic terms instead of
names of specific substances may be too unspecific whilst not
guaranteeing sensitivity. However, although the generic terms
produce a large number of hits, when combined with carefully
thought out terms for other parts of the question (e.g., biological
targets), they help search tools cover a larger spectrum. To our
knowledge, this aspect has not yet been systematically
investigated. One approach may be to develop search
strategies for prototypical stressors or model compounds
chosen from reliable resources like EURL ECVAM (European
Union Reference Laboratory, European Centre for the Validation
of Alternative Methods), for the methods/models validation
(Sund and Deceuninck, 2021).
Another approach to support the development of adequate
search strategies would be to evaluate a priori the chemical
applicability domain of specific KEs. A proof of concept used
the case of ‘PPARγ dysregulation’ to characterize the chemical
domain of PPARγ full agonists (Al Sharif et al., 2017).
Approaches for chemical screening to capture MIEs relevant
to human health have been proposed for a multitude of
human relevant targets by the Danish database (qsar.food.dtu.
dk/), for hepatic steatosis (Gadaleta et al., 2018) and for targets of
pharmaceutical relevance (Allen et al., 2016). Similarly, attempts
for chemical screening across environmental species and targets
relevant to aquatic toxicology have been also proposed (Bauer
et al., 2018; Sapounidou et al., 2021). A notable artificial
intelligence based in silico approach called AOP4EUpest
(biomedicale.parisdescartes.fr/aop4EUpest/home.php), is a web
server that has been developed to employ text-mining and graph
theory approaches for identification of literature that links
specific pesticides with AOP events.
Further research is necessary to establish to what extent
devising search strategies including terms related to specific
chemical stressors would be suitable to retrieve negative evidence
and whether they may compound publication bias or limit the
applicability domain of an AOP. Such research should serve to
develop a set of recommendations for literature search algorithms
adapted to the retrieval of EMmechanistic data forAOPdevelopment.
In addition, development of AOPs should be seen as an
interdisciplinary framework, as it involves different and
complementary expertise (toxicologists, biochemists,
bioinformatics scientists, etc.), in order to decipher the most
complete picture of the biological complexity of systems.
Critical Appraisal
Some critical appraisal tools of the risk-of-bias of
individual studies are commonly used for risk assessment
(e.g., ToxRTool. ec.europa.eu/jrc/en/scientific-tool/toxrtool-
toxicological-data-reliability-assessment-tool), and some have
been adapted to cater for the appraisal like the SciRAP
protocol (Roth et al., 2021). ToxRTool provides
comprehensive criteria and guidance for evaluations of the
inherent quality of data, making the reliability evaluation
process of assigning reliability categories more transparent and
harmonised. Automation doesn’t apply to these tools yet nor
would in the foreseeable future (Figure 1). Therefore, the focus at
this stage should fall on the expertise of the evaluator and the
inter-rater protocol that is followed. Simple approaches based on
formulating clearly framed questions (i.e., decision tree) may be
of help not only for critical appraisal but also for other aspects of
the process, like PF (Morgan et al., 2018). This conceptual
modelling is a transparent and coherent approach that
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facilitates the integration and interpretation of knowledge across
the whole SR process (Roth et al., 2020).
Weight-Of-Evidence
Similarly when it comes to integrating and synthesizing the
overall body of evidence, WoE approaches developed
specifically to assess whether specific substances are EDs and
are not adapted to establish confidence in individual KERs or the
biological plausibility of AOPs (Vandenberg et al., 2016). The
OECD guidance document describes relevant criteria and
methods for both the WoE for KERs and overall assessment
of the AOPs that can be equally applied to systematically retrieved
evidence (Becker et al., 2015). This existing guidance is aligned
with the work of Meek et al. (2014) and adapts Bradford-Hill
considerations to the specific context of assessing and integrating
mechanistic evidence. Again, applications of this WoE method
invariably rely on expert judgment and emphasis should be here
on documenting the process and rationale transparently, and it is
questionable whether automation of the process is even desirable.
CLOSING REMARKS
It is recognized that many of the EM AOPs that are currently
available in the AOP-wiki are incomplete, and often remain in that
state for a relatively long period of time. Indeed, only 26 of the 80
AOPs listed in Table 1, or about 33%, are considered either “Open
for adoption” or “Open for citation or comment” by their authors,
and only seven AOPs (9%) are OECD endorsed. Overall, it is clear
that there is a need to incentivize and encourage completion of
initiated AOPs. First, development of an AOP can be perceived as a
daunting task, requiring the knowledge and evidence to describe the
different KEs and KERs, including establishing causality and
essentiality, documenting dose and time concordance, etc.
Second, many AOP authors, in particular those from academia,
feel that there is insufficient professional recognition for the scholarly
investment that is required for formal AOP development, review and
endorsement (Knapen, 2021; Svingen et al., 2021). A number of
initiatives are being taken to address these challenges. For example,
AOP authors who add their AOP under development to the OECD
work plan are entitled to free guidance and coaching by an AOP
expert, ensuring completion of the AOP following the official
OECD’s AOP development principles. Also, several journals,
including Environmental Toxicology and Chemistry and
Environmental and Molecular Mutagenesis, have launched a new
“AOP Report” article type, allowing the publication of AOPs,
individual KERs, or small AOP networks. This provides authors
with a peer-reviewed publication, one of the main relevant academic
output parameters worldwide. These journals have entered into an
agreement with OECD allowing the accepted journal article,
including the reviewed AOP, to directly enter the OECD’s
endorsement process without going through the OECD’s
scientific review process.
In this context, resources such as time and access to literature
remain considerable barriers to the implementation of EBM to
AOP development. Echoing the views expressed in Svingen et al.
(2021), systematic evidence mapping may support PF in
complementing canonical knowledge and identifying KERs for
which SRs is appropriate. Indeed, given that EBM are often
energy- and time-consuming, scientists should be selective
FIGURE 1 | Overview of EBM processes for KER development amenable to automation with illustrative supporting tools and resources.
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about when a SR is needed, in order to keep the barrier to AOP
development, and completion of initiated AOPs, sufficiently low.
A number of MLT that have been or are being developed can
support the earlier stages of SR adapted to AOP development (i.e.,
PF, search strategies design). Their implementation for information
retrieval ought to be validated and compared with manual methods
for completeness to avoid introducing potential biases. It also is
unclear whether automated methods would be compatible with the
demands for transparently documented appraisal of the quality of
individual pieces of evidence or the evaluation strength of the overall
body of evidence. The development of MLT to support evidence-
based AOP development is a promising field, that is complementary
to already existing approaches, but that will nonetheless require a
considerable validation effort before full implementation.
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